Literature DB >> 26858452

A critical role for alternative polyadenylation factor CPSF6 in targeting HIV-1 integration to transcriptionally active chromatin.

Gregory A Sowd1, Erik Serrao1, Hao Wang1, Weifeng Wang1, Hind J Fadel2, Eric M Poeschla3, Alan N Engelman4.   

Abstract

Integration is vital to retroviral replication and influences the establishment of the latent HIV reservoir. HIV-1 integration favors active genes, which is in part determined by the interaction between integrase and lens epithelium-derived growth factor (LEDGF)/p75. Because gene targeting remains significantly enriched, relative to random in LEDGF/p75 deficient cells, other host factors likely contribute to gene-tropic integration. Nucleoporins 153 and 358, which bind HIV-1 capsid, play comparatively minor roles in integration targeting, but the influence of another capsid binding protein, cleavage and polyadenylation specificity factor 6 (CPSF6), has not been reported. In this study we knocked down or knocked out CPSF6 in parallel or in tandem with LEDGF/p75. CPSF6 knockout changed viral infectivity kinetics, decreased proviral formation, and preferentially decreased integration into transcriptionally active genes, spliced genes, and regions of chromatin enriched in genes and activating histone modifications. LEDGF/p75 depletion by contrast preferentially altered positional integration targeting within gene bodies. Dual factor knockout reduced integration into genes to below the levels observed with either single knockout and revealed that CPSF6 played a more dominant role than LEDGF/p75 in directing integration to euchromatin. CPSF6 complementation rescued HIV-1 integration site distribution in CPSF6 knockout cells, but complementation with a capsid binding mutant of CPSF6 did not. We conclude that integration targeting proceeds via two distinct mechanisms: capsid-CPSF6 binding directs HIV-1 to actively transcribed euchromatin, where the integrase-LEDGF/p75 interaction drives integration into gene bodies.

Entities:  

Keywords:  CFIm68; CPSF6; HIV-1; LEDGF; integration

Mesh:

Substances:

Year:  2016        PMID: 26858452      PMCID: PMC4776470          DOI: 10.1073/pnas.1524213113

Source DB:  PubMed          Journal:  Proc Natl Acad Sci U S A        ISSN: 0027-8424            Impact factor:   11.205


  61 in total

1.  HIV integration site selection: analysis by massively parallel pyrosequencing reveals association with epigenetic modifications.

Authors:  Gary P Wang; Angela Ciuffi; Jeremy Leipzig; Charles C Berry; Frederic D Bushman
Journal:  Genome Res       Date:  2007-06-01       Impact factor: 9.043

2.  Simian virus 40 large T antigen's association with the CUL7 SCF complex contributes to cellular transformation.

Authors:  Jocelyn S Kasper; Hiroshi Kuwabara; Takehiro Arai; Syed Hamid Ali; James A DeCaprio
Journal:  J Virol       Date:  2005-09       Impact factor: 5.103

3.  An interaction between U2AF 65 and CF I(m) links the splicing and 3' end processing machineries.

Authors:  Stefania Millevoi; Clarisse Loulergue; Sabine Dettwiler; Sarah Zeïneb Karaa; Walter Keller; Michael Antoniou; Stéphan Vagner
Journal:  EMBO J       Date:  2006-10-05       Impact factor: 11.598

4.  Biochemical and genetic analyses of integrase-interacting proteins lens epithelium-derived growth factor (LEDGF)/p75 and hepatoma-derived growth factor related protein 2 (HRP2) in preintegration complex function and HIV-1 replication.

Authors:  Nick Vandegraaff; Eric Devroe; Fanny Turlure; Pamela A Silver; Alan Engelman
Journal:  Virology       Date:  2005-12-09       Impact factor: 3.616

5.  An essential role for LEDGF/p75 in HIV integration.

Authors:  Manuel Llano; Dyana T Saenz; Anne Meehan; Phonphimon Wongthida; Mary Peretz; William H Walker; Wulin Teo; Eric M Poeschla
Journal:  Science       Date:  2006-09-07       Impact factor: 47.728

6.  A role for LEDGF/p75 in targeting HIV DNA integration.

Authors:  Angela Ciuffi; Manuel Llano; Eric Poeschla; Christian Hoffmann; Jeremy Leipzig; Paul Shinn; Joseph R Ecker; Frederic Bushman
Journal:  Nat Med       Date:  2005-11-27       Impact factor: 53.440

7.  LEDGF/p75 determines cellular trafficking of diverse lentiviral but not murine oncoretroviral integrase proteins and is a component of functional lentiviral preintegration complexes.

Authors:  Manuel Llano; Maria Vanegas; Oliver Fregoso; Dyana Saenz; Susan Chung; Mary Peretz; Eric M Poeschla
Journal:  J Virol       Date:  2004-09       Impact factor: 5.103

8.  HIV integration targeting: a pathway involving Transportin-3 and the nuclear pore protein RanBP2.

Authors:  Karen E Ocwieja; Troy L Brady; Keshet Ronen; Alyssa Huegel; Shoshannah L Roth; Torsten Schaller; Leo C James; Greg J Towers; John A T Young; Sumit K Chanda; Renate König; Nirav Malani; Charles C Berry; Frederic D Bushman
Journal:  PLoS Pathog       Date:  2011-03-10       Impact factor: 6.823

9.  Role of PSIP1/LEDGF/p75 in lentiviral infectivity and integration targeting.

Authors:  Heather M Marshall; Keshet Ronen; Charles Berry; Manuel Llano; Heidi Sutherland; Dyana Saenz; Wendy Bickmore; Eric Poeschla; Frederic D Bushman
Journal:  PLoS One       Date:  2007-12-19       Impact factor: 3.240

10.  LEDGF/p75 functions downstream from preintegration complex formation to effect gene-specific HIV-1 integration.

Authors:  Ming-Chieh Shun; Nidhanapati K Raghavendra; Nick Vandegraaff; Janet E Daigle; Siobhan Hughes; Paul Kellam; Peter Cherepanov; Alan Engelman
Journal:  Genes Dev       Date:  2007-07-15       Impact factor: 11.361

View more
  120 in total

1.  A Novel Phenotype Links HIV-1 Capsid Stability to cGAS-Mediated DNA Sensing.

Authors:  Mohammad Adnan Siddiqui; Akatsuki Saito; Upul D Halambage; Damien Ferhadian; Douglas K Fischer; Ashwanth C Francis; Gregory B Melikyan; Zandrea Ambrose; Christopher Aiken; Masahiro Yamashita
Journal:  J Virol       Date:  2019-07-30       Impact factor: 5.103

Review 2.  Integration site selection by retroviruses and transposable elements in eukaryotes.

Authors:  Tania Sultana; Alessia Zamborlini; Gael Cristofari; Pascale Lesage
Journal:  Nat Rev Genet       Date:  2017-03-13       Impact factor: 53.242

Review 3.  Barriers for HIV Cure: The Latent Reservoir.

Authors:  Sergio Castro-Gonzalez; Marta Colomer-Lluch; Ruth Serra-Moreno
Journal:  AIDS Res Hum Retroviruses       Date:  2018-08-28       Impact factor: 2.205

4.  Nuclear pore heterogeneity influences HIV-1 infection and the antiviral activity of MX2.

Authors:  Melissa Kane; Stephanie V Rebensburg; Matthew A Takata; Trinity M Zang; Masahiro Yamashita; Mamuka Kvaratskhelia; Paul D Bieniasz
Journal:  Elife       Date:  2018-08-07       Impact factor: 8.140

5.  PF74 Inhibits HIV-1 Integration by Altering the Composition of the Preintegration Complex.

Authors:  Muthukumar Balasubramaniam; Jing Zhou; Amma Addai; Phillip Martinez; Jui Pandhare; Christopher Aiken; Chandravanu Dash
Journal:  J Virol       Date:  2019-03-05       Impact factor: 5.103

6.  Immune Control of HIV.

Authors:  Muthukumar Balasubramaniam; Jui Pandhare; Chandravanu Dash
Journal:  J Life Sci (Westlake Village)       Date:  2019-06

Review 7.  Multifaceted HIV integrase functionalities and therapeutic strategies for their inhibition.

Authors:  Alan N Engelman
Journal:  J Biol Chem       Date:  2019-08-29       Impact factor: 5.157

8.  Capsid-CPSF6 interaction: Master regulator of nuclear HIV-1 positioning and integration.

Authors:  Vasudevan Achuthan; Jill M Perreira; Jenny J Ahn; Abraham L Brass; Alan N Engelman
Journal:  J Life Sci (Westlake Village)       Date:  2019-06

9.  Molecular Mechanisms for CFIm-Mediated Regulation of mRNA Alternative Polyadenylation.

Authors:  Yong Zhu; Xiuye Wang; Elmira Forouzmand; Joshua Jeong; Feng Qiao; Gregory A Sowd; Alan N Engelman; Xiaohui Xie; Klemens J Hertel; Yongsheng Shi
Journal:  Mol Cell       Date:  2017-12-21       Impact factor: 17.970

10.  Minute Virus of Canines NP1 Protein Interacts with the Cellular Factor CPSF6 To Regulate Viral Alternative RNA Processing.

Authors:  Yanming Dong; Olufemi O Fasina; David J Pintel
Journal:  J Virol       Date:  2019-01-04       Impact factor: 5.103

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.